GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. Read the full story.
GigaGen announced that it is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19, the pandemic coronavirus that has been sweeping the world and for which humans have no innate immunity. Based in South San Francisco, GigaGen spent the first seven years of its existence developing its single cell technology drug discovery and […]
Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. But a small South San Francisco startup thinks its approach could be even better. Read the full […]
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. Read the full press release.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2020-03-30 13:50:052020-05-13 13:53:47GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2020-03-19 13:41:362020-05-13 15:12:59Pharma’s Almanac: CEO Dave Johnson shares his thoughts in Roundtable: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?
“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2020-02-03 18:13:202020-02-03 18:20:02GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts
With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2020-01-07 15:32:072020-01-09 15:34:40Scrip: CEO Dave Johnson Discusses Commercializing Advanced Therapies in Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business and Investment
A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients. IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-12-10 14:54:572019-12-13 14:55:28BioSpace: GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage
Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday. […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-09-23 14:46:062020-05-13 15:40:47Biocom: CSO Adam Adler named a Biocom Catalyst Award Winner
Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-08-02 08:18:092019-09-09 08:28:29PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-07-19 07:22:592019-07-20 07:24:04GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-04-19 06:32:552019-04-24 06:34:01BioSpace: 6 Award-Winning Life Science Companies in the Bay Area
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-03-25 05:30:542019-03-25 05:31:35GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies
“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group. As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-03-13 05:41:142019-03-13 05:44:40STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-02-25 09:26:572019-02-25 09:26:57GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-12-07 05:55:582018-12-07 05:55:58GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-11-12 14:36:122018-11-12 14:37:53GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
BioSpace: GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. Read the full story.
Big4Bio: GigaGen Focuses Its Technology to Address COVID-19 Pandemic
GigaGen announced that it is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19, the pandemic coronavirus that has been sweeping the world and for which humans have no innate immunity. Based in South San Francisco, GigaGen spent the first seven years of its existence developing its single cell technology drug discovery and […]
FierceBiotech: GigaGen jumps into COVID-19 arena with polyclonal antibodies
Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. But a small South San Francisco startup thinks its approach could be even better. Read the full […]
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. Read the full press release.
Pharma’s Almanac: CEO Dave Johnson shares his thoughts in Roundtable: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?
The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for […]
GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts
“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable […]
Scrip: CEO Dave Johnson Discusses Commercializing Advanced Therapies in Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business and Investment
With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health […]
BioSpace: GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage
A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients. IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them […]
Biocom: CSO Adam Adler named a Biocom Catalyst Award Winner
Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday. […]
PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People
Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell […]
GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]
BioSpace: 6 Award-Winning Life Science Companies in the Bay Area
There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life […]
GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it […]
STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture
“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group. As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group […]
GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in […]
GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for […]
GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of […]
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]
GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]